Brief: Vaxxinity Completes Enrollment In Phase 3 Trial Of UB-612 Covid-19 Vaccine

Vaxxinity

24/10/2022 13:13

Oct 24 (Reuters) - Vaxxinity Inc  VAXX.O :
    * VAXXINITY COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL
TRIAL
OF UB-612 COVID-19 VACCINE HETEROLOGOUS BOOSTER CANDIDATE AND
INITIATES ROLLING SUBMISSION FOR PROVISIONAL APPROVAL IN
AUSTRALIA
    * VAXXINITY COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL
TRIAL
OF UB-612 COVID-19 VACCINE HETEROLOGOUS BOOSTER CANDIDATE AND
INITIATES ROLLING SUBMISSION FOR PROVISIONAL APPROVAL IN
AUSTRALIA

Source text for Eikon:  ID:nGNX4Z3fvC 
Further company coverage:  VAXX.O 
 ((Reuters.Briefs@thomsonreuters.com;))